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Abstract
Background: Informed consent of trial participants is both an ethical and a legal requirement. When facing a
decision about trial participation, potential participants are provided with information about the trial and have the
opportunity to have any questions answered before their degree of ‘informed-ness’ is assessed, usually subjectively,
and before they are asked to sign a consent form. Currently, standardised methods for assessing informed consent
have tended to be focused on aspects of understanding and associated outcomes, rather than on the process of
consent and the steps associated with decision-making.
Methods: Potential trial participants who were approached regarding participation in one of three randomised
controlled trials were asked to complete a short questionnaire to measure their deliberation about trial participation. A
total of 136 participants completed the 10-item questionnaire (DelibeRATE) before they made an
explicit decision about trial participation (defined as signing the clinical trial consent form). Overall DelibeRATE scores
were compared and investigated for differences between trial consenters and refusers.
Results: No differences in overall DelibeRATE scores were identified. In addition, there was no significant difference
between overall score and the decision to participate, or not, in the parent trial.
Conclusions: To our knowledge, this is the first study to prospectively measure the deliberation stage of the informed
consent decision-making process of potential trial participants across different conditions and clinical areas. Although
there were no differences detected in overall scores or scores of trial consenters and refusers, we did identify some
interesting findings. These findings should be taken into consideration by those designing trials and others interested
in developing and implementing measures of potential trial participants decision making during the informed consent
process for research.
Trial registration: International Standard Randomised Controlled Trial Number (ISRCTN) Register ISRCTN60695184
(date of registration: 13 May 2009), ISRCTN80061723 (date of registration: 8 March 2010), ISRCTN69423238
(date of registration: 18 November 2010)
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Background
Informed consent for research participation is an ethical
and legal requirement that covers aspects such as capacity,
disclosure, understanding, voluntariness and permission
[1]. There is a regulatory requirement to provide informa-
tion about these key features to potential clinical trial
participants and to assess, usually subjectively, their
understanding of said information and recognition that
participation is optional before their consent is obtained
[2,3]. Current guidelines that regulate informed consent
for clinical trials tend to focus more on the information
provided to potential trial participants than on the
understanding and quality of the decision that these
individuals reach [3]. The subjective assessment of
informed consent for clinical trials, and the potential
difficulties associated with it, has led several studies to
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develop objective measures of informed consent for clin-
ical trials [4,5]. These objective measures of informed con-
sent are often specific to a particular population or
clinical condition and largely focus on understanding
of (some or all of ) the key elements of informed con-
sent, namely: capacity, disclosure, understanding, vol-
untariness and permission [6-10]. Many of the
developed tools are study-specific, but some validated
measures exist. Probably the most widely used validated
measure is the Quality of Informed Consent (QuIC) tool,
which was developed in cancer clinical trials [6]. The
QuIC measures aspects of both objective comprehension
(for example, understanding the trial) and subjective un-
derstanding (for example, ‘informed-ness’). More recent
validated measures of informed consent for clinical trials
are focused on particular aspects of informed consent,
such as randomisation and placebo [11] and the thera-
peutic misconception [12].
Some of the objective measures of informed consent
for clinical trials tend to conceptualise and operationalise
aspects of understanding in relation to clinical trials in a
somewhat limited way. Several focus on knowledge of the
trial in a general sense, and others check a participant’s
ability to correctly recall information without considering
comprehension; but all lack consideration of other aspects
that may be important to the decision-making process
(for example, preference construction, affective forecasting
and determining what matters most to an individual)
[6-12]. As such, the current evidence base on informed
consent measures highlights a focus on knowledge and
understanding, which, though important building blocks,
are not the only components required for decision-
making. There also remains a lack of recognition of the
importance of the ‘process’ in many of these measures,
evidenced by a focus on outcomes rather than on the
steps leading up to such outcomes [6-12]. This is of
particular relevance when considering that informed
consent is defined as ‘a process by which a subject
voluntarily confirms his or her willingness to participate
in a particular trial, after having been informed of all as-
pects of the trial that are relevant to the subject’s decision
to participate’ [3]. Existing measures of informed consent
tend to make implicit assumptions about the type of infor-
mation that is relevant to a potential participant’s
decision-making and based largely on the information or
concepts prespecified in the guidance [6-12]. Moreover,
most of the interventions to date that aim to improve
informed consent for randomised controlled trials are
focused on improving understanding [4,5]. Evaluation
of these interventions has not led to identification of
an optimal method, and, as such, it may be import-
ant to consider new interventions focused on the
decision-making process and measures relevant for
their assessment [13].
The majority of studies in which researchers have
assessed informed consent for clinical trials have in-
volved implementation of tools to measure outcomes
after an explicit decision was made (that is, after consent
was given or not) [4,5]. Measuring aspects of decision-
making after a decision has been made may be susceptible
to bias due to the influence of outcomes attributed to the
decision [14]. For example, a decision about trial entry
might be viewed more positively if participants receive (or,
in a blinded trial, believe they have received) the interven-
tion for which they had a preference and vice versa. It has
been suggested that the decision-making process for treat-
ment choices can be separated into the categories of delib-
eration about processes and determination of decisions and
that these steps require different evaluation approaches
[14]. A potential advantage of this is that measuring delib-
eration could provide a measure of the decision-making
process without its being biased by any influences derived
from decision-making outcomes. The deliberation step
of decision-making has been proposed to have several
overlapping stages, ranging from information-seeking,
information-processing and assessing knowledge suffi-
ciency to imagining counterfactuals, emotional process-
ing, affective forecasting, preference construction and
readiness to make a choice [14]. These steps come to-
gether to inform and determine the decision stage [14].
Some of the stages of deliberation involve aspects that
are also traditionally associated with aspects of informed
consent, specifically seeking information, processing infor-
mation and assessing knowledge sufficiency and imagining
pros and cons. Individuals’ consideration of whether to
provide informed consent for clinical trials as a process
can be broken down into two stages: deliberation (trial is
introduced, patient information leaflet is provided and a
discussion about participation is conducted) and determin-
ation (decision to participate or not as demonstrated by
the signing of a consent form). There is some evidence in
the literature that, during explicit deliberation about pre-
ferences, potential trial participants are more likely to
become more uncertain and amenable to trial participa-
tion [15]. This finding supports the notion that measuring
deliberation may provide data that is not biased by deci-
sional outcomes, but illustrative of the overall consent
process [15]. It also supports a hypothesis that deliberation
during the informed consent process may differ between
trial consenters and refusers. For example, consenters
may feel more ready to make a decision and corres-
pondingly may assess their state of deliberation as
higher compared to refusers, or vice versa. In further
support of this hypothesis, studies have shown a poten-
tial difference between trial consenters and refusers on
specific decision-making outcomes. Satisfaction (relat-
ing to the decision) has been suggested to be higher in
trial consenters than in refusers, and decisional
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conflict (a measure of uncertainty) has been shown to be
lower amongst consenters [16,17].
Rather than being focused solely on the exact informa-
tion that is provided in the trial information leaflet and
using informed consent measures as an assessment of
recall, which has tended to be the focus to date, a new
approach to assessing the decision-making process in
clinical trials could be advantageous. Specifically, by
evaluating more general aspects of the decision and the
associated process, which are operationalised in a way
that focuses on the individual. A further benefit of a
more general decision-making measure for clinical trial
participation could be realised by developing a measure
that is amenable to different trial contexts, thus providing
a way of improving comparisons across trials and increas-
ing the generalisability of findings in individual studies
and meta-analyses.
To date, to our knowledge, there have been no studies
in which researchers have developed a tool to measure
informed consent to participate in clinical trials that
encompasses aspects of the decision-making process
beyond ‘understanding’ and that are aimed at measuring
the process before an explicit decision is made. In this
study, we report the use of a tool (DelibeRATE) to measure
the deliberation stage of the decision-making process in the
context of decisions about trial participation. Specifically,
we investigated potential trial participants’ deliberation
when making a decision about trial participation and
whether this deliberation differs between trial consenters
and refusers.
Methods
Participants
This study is nested within three clinical trials that were
actively recruiting patients at the time it was carried out.
Appropriate trials were purposively selected from among
the Centre for Healthcare Randomised Trials (CHaRT)
portfolio of ongoing clinical trials. CHaRT is a registered
clinical trials unit of the UK Clinical Research Collabor-
ation which specialises in pragmatic trials of complex
interventions. The chief investigators of the identified
clinical trials were approached, and their agreement was
sought prior to study commencement.
Potential trial participants were identified from among
individuals approached in each of the actively recruiting
clinical trials. Two of the trials were surgical trials, one in
gynaecology recruiting postmenopausal women (ISRCTN
60695184 (date of registration: 13 May 2009) and the
other in general surgery recruiting from a broad popula-
tion (ISRCTN 8006172 (date of registration: 8 March
2010)). The third trial was a placebo-controlled drug trial
set within urology, also recruiting from a broad population
(ISRCTN 69423238 (date of registration: 18 November
2010). More details on each of the included trials can be
found in Table 1. To minimise burden for individual
recruiters, at least three centres per trial were asked to
participate, each providing 20 completed questionnaires
per site to give a target total of 180 completed question-
naires for analysis. At the time we developed this study,
no published studies in which the DelibeRATE tool was
used were available to inform the sample size. The infor-
mal sample size calculation was based upon obtaining 200
recruits overall from 5 recruiting trials with 10 recruits
per centre and 40 per trial. Due to the administrative
burden, recruitment goals were not achieved at two of
the five sites.
DelibeRATE tool development
The development of the DelibeRATE tool was not part
of this study and has been reported elsewhere [14,18]. In
brief, items included in the original DelibeRATE tool
were based on the conceptualisation of the decision-
making process as one of deliberation (which includes
a predecisional process and an act of decision deter-
mination) rather than on the outcome of the decision
[14]. Through iterative group work, items that mapped
onto the concept of deliberation were developed and
operationalised (that is, recognising that decisions are
needed, identifying options, describing options and
deliberating about the attributes) prior to making
judgements and comparisons and constructing prefer-
ences. The scale was used in a study in which researchers
evaluated the impact of a web-based decision-making aid
for breast cancer treatment options [18]. This previous
study showed the items in the tool to have good internal
reliability, with Cronbach’s α values of 0.945 (preinterven-
tion) and 0.960 (postintervention) [18]. The previously
published tool had undergone further refinement by the
development team before being used in the study reported
in this article. Specifically, previously each item in the
published tool was rated on a seven-point scale anchored
by ‘strongly agree’ and ‘strongly disagree’ [18]. In the up-
dated version of the tool that was provided, and used, for
this project, the responses for each item had been revised
to ‘yes’, ‘no’ and ‘unsure’, which was a pragmatic decision
by the developers (from [18]) to make it easier to score.
Also, the previously published tool was composed of nine
items. However, the tool provided, and used in this study,
contained ten items, with one of them (item D3 from
[18]) split into two separate items—advantages (item 3)
and disadvantages (item 4)—rather than being combined.
The DelibeRATE tool was originally developed to meas-
ure decisions about treatment [18]. As such, the wording
was amended (by KG and JC) to ensure that items were
explicit about the decision being related to trial participa-
tion. As such, all of the items in the tool were adapted to
incorporate the phrase ‘of participating in the trial or not’.
The modified DelibeRATE tool is shown in Figure 1 No
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Table 1 Characteristics of trials included in the DelibeRATE studya
Trial characteristics Trial 1 Trial 2 Trial 3
Clinical condition Vaginal prolapse Haemorrhoids Ureteric stones
Trial design RCT and comprehensive cohort Simple parallel design Simple parallel design
Sample size, N (n) 4,500 (2,250 randomised) 800 1,200
Recruitment rate (%) 49 74 56
Arms 3 in each repair arm (4 different interventions) 2 3
Intervention Surgery (RCT split by primary or secondary repair Surgery Drug
Primary repair randomisation 1. Traditional excisional haemorrhoidectomy 1. Calcium channel blocker
1. Standard repair 2. Stapled haemorrhoidopexy 2. α blocker
2. Standard repair with biological mesh 3. Placebo
3. Standard repair with nonabsorbable mesh
Secondary repair randomisation
1. Standard repair
2. Standard repair with nonabsorbable mesh
3. New repair with mesh kit
Blinding Participants and outcome assessors
(for patient-reported outcomes)
Participants and outcome
assessors (for patient-reported
outcomes)
Participants, caregivers
and outcome assessors
Number of sites 15 31 24
Primary outcome (clinical or
patient-reported and timing)
Patient-reported at 2 years
postrandomisation
Patient-reported at 2 years
postrandomisation
Clinical at 4 weeks and
patient-reported at 12
weeks postrandomisation
Parent trial participant characteristics
Median age (IQR) 61 (52 to 68) 49 (20 to 40) 44 (34 to 52)
Sex (% females) 100 48 19
aRCT, Randomised controlled trial.
Figure 1 Distribution of overall DelibeRATE scores. DelibeRATE scores ranged from 0 to 20. No participants scored less than 11.
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validation of the scale was conducted in the context of
trial participation decisions.
Data collection
Following introduction of the parent trial by the recruiter,
as per individual trial protocols, each patient was given
the DelibeRATE questionnaire. The questionnaire included
a short description of the study and instructions for
completion. Once the patients completed the question-
naire, they either returned it sealed in an envelope to
the recruiter for posting to the study office or, if they
completed it at home, returned it to the study office in
the post, depending on the nature of the recruitment
process in each individual trial. The study questionnaire
was composed of a short demographic section and the
DelibeRATE tool. The DelibeRATE tool is a short, ten-item
tool which requires each question to be rated on a three-
level Likert scale and takes participants approximately 5 mi-
nutes to complete (Figure 2). The recruiters were asked to
ensure that the questionnaire was completed before the de-
cision to participate in the parent trial was made, which, for
the purposes of this study, occurred before explicit written
consent to participate in the parent trial was recorded. In
addition to completing the DelibeRATE questionnaire, par-
ticipants were asked to answer questions about their age,
sex, educational attainment and previous trial participation.
Figure 2 The DelibeRATE tool.
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The recruiter was asked to complete a short data form
about each potential participant. The following data
were recorded on the form: who provided the potential
participant with the patient information leaflet for the
trial, who had the consent discussion with the potential
participant, how long the potential participant had to
decide about taking part in the trial and whether the
patient consented to participate in the clinical trial for
which they were initially approached.
Analysis
Participant and trial characteristics are presented using
summary statistics as appropriate. The maximum Delib-
eRATE questionnaire overall score was 20, with each item
being scored from 0 to 2 (0 = No, 1 = Unsure, 2 = Yes).
The overall DelibeRATE score and individual question
scores were analysed and are presented using summary
statistics such as the median and interquartile ranges or
number per category and percentage as appropriate. The
higher the score, the readier potential participants were
to making a decision about trial entry. A generalised
estimating equation approach was planned to analyse
the DelibeRATE score, but it was not carried out
because the participating recruiting centres and recruiters
were fewer than anticipated. Instead, to determine
whether there was a difference in DelibeRATE scores
between participants consenting or not, we performed a
Mann–Whitney U test (two-sided, 5% significance level).
Similarly, differences in the time taken to decide were
tested using a Mann–Whitney U test or Kruskal-Wallis
test as appropriate. Correlations were calculated using
Spearman’s correlation statistic.
The study was approved by the North of Scotland
Research Ethics Committee 1 (11/AL/0271). As the
study was multicentred, the original ethics application,
as approved, included appropriate review of the research
with respect to recruitment of participants across all
included sites. NHS Research and Development approval
was sought from individual committees for each of
the sites and included NHS Ayrshire & Arran, NHS
Grampian, NHS Highland, Central Manchester University
Hospitals NHS Foundation Trust, County Durham and
Darlington NHS Foundation Trust, Plymouth Hospitals
NHS Trust and South Devon Healthcare NHS Foundation
Trust. Participants were not asked to complete an add-
itional consent form for this study. Instead, consent was
implied by completion and return of the questionnaire as
approved by the Research Ethics Committee (see above).
Results
Participant characteristics
A total of 136 potential trial participants completed the
DelibeRATE questionnaire between September 2011 and
June 2013. Table 2 provides details of the demographic
characteristics of the sample of participants who com-
pleted and returned the questionnaire. They represented
three clinical trials and seven individual sites, with five
sites recruiting to trial 1, four sites recruiting to trial 2
and three sites recruiting to trial 3 (Table 2). There were
more females (75%) than males (25%) in the respondent
sample, which was due to one of the trials (trial 1) being
set within gynaecology and to that trial contributing
Table 2 Participant demographics
Demographic characteristics n (%)
Number of participants by trial
1 81 (60)
2 27 (20)
3 28 (20)
Number of participants by site
(recruiting to trial 1, 2 or 3)
1 (trial 1, 2 and 3) 46 (34)
2 (trial 2 and 3) 14 (10)
3 (trial 3) 8 (6)
4 (trial 2) 6 (4)
5 (trial 1) 18 (13)
6 (trial 1 and 2) 25 (18)
7 (trial 1 and 2) 19 (14)
Median age, yr (IQR) 55 (43 to 65)
Males 34 (25)
Educational attainmenta
No formal education 38 (28)
Secondary 59 (44)
Higher 38 (28)
Previous trial participation (number of trials)
0 120 (88)
1 13 (10)
2 2 (2)
3 1 (1)
Person providing patient info leaflet
Research nurse 111 (82)
Consultant 8 (6)
Specialist Registrar 1 (1)
Other 16 (12)
Person taking consent
Research nurse 109 (81)
Consultant 7 (5)
Specialist registrar 2 (1)
Other 17 (13)
Consented to trial 128 (94)
Median time to make decision, days (IQR) 1 (0.04 to 14)
aData for one respondent are missing.
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significantly more participants (60%) than either of the
other two. The median age of the participants, 55 years,
also reflected the specific context of trial 1 because it is
a trial set within a condition in postmenopausal women.
Participants’ ages across the sample ranged from 19 to
81 years. The participants had varied levels of education,
with 28% having no formal education. In relation to
demographics concerning trial characteristics, only a
small number (12%) of the participants had previously
taken part in a clinical trial. Research nurses were most
often the person providing the patient with the trial
information leaflet (82%) and the person responsible for
taking consent for the clinical trial (81%). The majority
(94%) of the participants who returned and completed
the DelibeRATE questionnaire consented to participate
in the trial. The time taken to decide about participating
in the trial ranged from 30 minutes to 24 weeks, with
the median time being 24 hours.
DelibeRATE scores
There was no significant difference in the overall Delib-
eRATE scores, with a median of 20 (IQR = 18 to 20).
The overall score ranged from 11 to 20, with only 5% of
participants scoring 15 or below (Table 3 and Figure 2).
Similarly, there was no significant difference in scores
for individual items in the DelibeRATE tool. However,
some items did exhibit more variability in respondents
answering ‘unsure’ and ‘no’ than others. For example,
though 84% of respondents scored item 4 as ‘Yes’, 12%
as ‘Unsure’ and 4% as ‘No’, items 6, 7 and 8 had similar
frequency distributions (Table 4). There was no signifi-
cant difference (median = 20 (IQR = 18 to 20) versus
median = 20 (IQR = 11 to 20); P = 0.669) between overall
scores for those who decided to participate versus those
who did not. There was evidence of a weak correlation of
age (Spearman’s correlation = −0.19; P = 0.29) to overall
score (Table 5), but not of a difference in the overall score
to other factors potentially predictive of poor understand-
ing (for example, educational attainment (P = 0.528)) or a
difference in previous trial participation (P = 0.859). Time
to decide (Table 5) did not vary according to who obtained
consent (research nurse versus others; P = 0.683), but did
according to trial (P < 0.001).
Discussion
Principal findings
This is the first study to prospectively measure the delib-
eration stage of decision-making for trial participation.
Moreover, this study has included potential participants
from a diverse range of trials across interventions,
Table 3 Distribution of overall DelibeRATE scoresa
Score n (%)
≤10 0 (0)
11 1 (1)
12 1 (1)
13 1 (1)
14 2 (1)
15 1 (1)
16 5 (4)
17 6 (4)
18 15 (11)
19 18 (14)
20 82 (62)
aFive participants are not included in this table due to missing data on
individual DelibeRATE items.
Table 4 Response frequency across DelibeRATE items
Item Response n (%)
1 Yes 134 (99)
Unsure 2 (1)
No 0 (0)
2 Yes 135 (99)
Unsure 1 (1)
No 0 (0)
3 Yes 126 (93)
Unsure 10 (7)
No 0 (0)
4a Yes 114 (84)
Unsure 16 (12)
No 5 (4)
5 Yes 129 (95)
Unsure 7 (5)
No 0 (0)
6b Yes 109 (81)
Unsure 23 (17)
No 2 (1)
7a Yes 116 (86)
Unsure 18 (13)
No 1 (1)
8a Yes 106 (79)
Unsure 25 (19)
No 4 (3)
9a Yes 130 (96)
Unsure 5 (4)
No 0 (0)
10b Yes 130 (97)
Unsure 3 (2)
No 1 (1)
aItem not completed by one participant. bItem not completed by two
participants.
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conditions and clinical areas (although the sample size
is small), both those who subsequently consented to
the respective trial and those who did not. There was
no difference in overall DelibeRATE scores or between
trial consenters and refusers. We identified additional
potential problems with decision-making for trial par-
ticipation from both the perspective of measurement
of the process and more generally in relation to the
overall trial.
The lack of a difference in DelibeRATE scores between
trial consenters and refusers requires reflection. The
most likely reasons for a lack of variability in the scores
of consenters and refusers are deficiencies in the tool
itself and the likelihood that the participants in this
study are an unrepresentative sample of all potential
recruits to the parent trials (reflected in the small num-
bers of refusers). Only 6% of those who completed the
DelibeRATE questionnaire went on to refuse entry into
the main trial, with 94% eventually consenting to partici-
pation. The lack of a statistically significant difference in
DelibeRATE scores between consenters and refusers is
not surprising, given the small number of refusers included
in the sample. It is also plausible that a higher degree of
variability between the two groups would be observed in a
larger and more representative sample of refusers. The
94% consent rate is not a true representation of the con-
sent rates in the parent trials, which had recruitment rates
(adjusted for DelibeRATE sites) of 77% (trial 1), 72% (trial
2) and 68% (trial 3), giving a combined consent rate of
72%. There are several explanations for this misrepresen-
tation from both a participant and a recruiter perspective.
From a participant perspective, it is likely that those
individuals who are unconditional refusers (whether
absolutely or temporally at this point in time) are unlikely
to engage in any research study, whether it be a clinical
trial or a less burdensome questionnaire-based study such
as this one. The other group of refusers, and the more in-
teresting one in relation to decision-making, are those
who are of two minds about participation. It is unlikely
that all of these ‘uncertains’ converted to trial consenters
and, as such, more likely that this group of individuals was
lost at an earlier stage of the study.
The other explanation for the sample in this study be-
ing overrepresented by trial consenters could be related
to the recruiter. For all trial recruiters, there is a pres-
sure to recruit maximum numbers of participants into
the trial, and, as such, implicit judgements about the
participants ‘fit’ for the trial may be made in advance of
or during the discussion about trial participation. In other
words, recruiters approach only potential participants
who they think will say yes so as not to waste time on
those who will refuse, ultimately improving recruitment
efficiency but having detrimental consequences for the
trial’s generalisability. There is evidence in the literature to
support the notion that recruiters make ‘off-protocol’
decisions about potential participants. For example, re-
searchers in one study reported recruiters’ targeting the
‘good study patient’, who were those perceived as ‘meticu-
lous, proactive and compliant’ with good communication
skills and strong social networks to support their partici-
pation [19]. In a recent study, Donovan and colleagues
found that both doctors and nurses struggle with their
role as ‘recruiters’ and make implicit judgements about
patients’ eligibility largely based on a lack of equipoise
[20]. Research nurses also report using nonverbal cues
from potential participants as a way to evaluate whether
these individuals are willing to participate (K Gillies,
personal communication). In addition, recruiters may
Table 5 DelibeRATE total score and time to decide by factor
Variable Factor Median (IQR) P-value
DelibeRATE total score Educational attainment 0.528
No formal education 20 (18 to 20)
Secondary 20 (18 to 20)
Higher 20 (20 to 20)
DelibeRATE total score Previous trial participation 0.859
Yes 20 (19 to 20)
No 20 (18 to 20)
Time to decide Trial <0.001
Trial 1 8 (0.08 to 35)
Trial 2 0.4 (0.02 to 7)
Trial 3 0.125 (0.08 to 1)
Time to decide Research nurse taking consent 0.683
Yes 1 (0.04 to 12)
No 0.125 (0.04 to 14)
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perceive DelibeRATE as a measure of their ability to
inform potential participants, even though they were
assured this was not the aim of the study. As such, they
may have changed their behaviour to select only appro-
priate or ‘good’ patients or may have spent more time
discussing aspects of the trial than would be standard
practice. However, it is unlikely that all recruiters
across the seven included sites attempted to elicit this
behaviour and, as such, would not be accountable for
the entire 94% consent rate.
With regard to the design of the study, it is likely that,
for a large proportion of participants included in this
study, the decision-making measurement was taken after
a commitment to the decision had already been made;
that is, the DelibeRATE questionnaire was measuring a
decision that had already been made rather than the de-
liberative process, which had happened earlier. This
speculation that the measurement was postcommitment
is further supported by the high overall scores seen in
the sample. These high scores may also be supportive of
the recruiters’ approaching only the ‘good’ participants,
but data on the number of questionnaires distributed
versus those returned would be required for this finding
to be more conclusive. Unfortunately, we did not collect
data on the specific response rate regarding participation
to this study. However, a very rough estimate of 87% for
the response rate can be made on the basis of the num-
ber of questionnaires actually distributed at sites (based
on data from three of the seven sites). This estimate,
along with the adjusted recruitment rate for each parent
trial, suggests that the proportion of trial refusers was
likely higher than 6% but that those participants were
not amenable to completing the DelibeRATE question-
naire. The final consideration regarding the influence of
study design on the results is the development of the
DelibeRATE tool. The tool was developed for use in a
treatment context, and, though the constructs being
measured (that is, those items related to the steps of
deliberation) would be the same irrespective of the index
decision, the framing of the constructs was changed
without assessment of their validity before use. There-
fore, any lack of difference in scores may also reflect
deficiencies in the tool in this context.
It is worth discussing in general how scores generated
from measures of informed consent (both outcomes
and process) would be operationalised in this context.
Whereas other measures of informed consent highlight
a deficit in outcomes postdecision, when it may be too
late to intervene, we measured aspects of the decision-
making ‘process’ for trial participation prospectively
and, as such, our study had the potential to detect ‘poor’
decisions as they were being made. Exactly how this or
similar measures would be operationalised requires
more thought. For example, if the maximum score is 20,
is there a requirement for all participants to achieve
100% on their decision-making process measure before
their subsequent consent is considered valid? Or is there
a threshold at which consent becomes acceptable, and is
this threshold based on the items’ having equal weighting
or are some more important than others? In this study,
95% of the participants scored ≥17 (85%), but does that
mean that the 5% who scored ≤16 (80%) gave suboptimal
consent, that is, that their decision process was not as
good as it could have been, and, as such, that their consent
should be questioned? Maybe a better assessment method
would be to follow up these participants over time and
investigate scores in relation to retention in the trial. It
may be that retention is in fact a better measure of
decision quality than recruitment and thus should be
explored in future design and analysis of measures of
decision-making about trial participation.
Strengths and limitations
The two main limitations of this study are (1) that the
study sample was composed predominantly of those
who subsequently consented to trial participation and
(2) the use of a tool to measure decision-making that
had not been designed and specifically validated for use
in a trial consent context. The tool was not formally
piloted, but was tested for comprehension amongst
colleagues. Therefore, the lack of variability in the
DelibeRATE scores could be due to a lack of validity
and reliability of the measurement instrument itself.
Further work required to validate this tool could include
(but is not limited to) pilot testing with potential partic-
ipants to assess face validity and explore item phrasing
and redundancy (using cognitive interviews) to investigate
content validity. Assessment of reliability, specifically in-
ternal consistency, could be conducted using Cronbach’s α
analysis of linked items and test–retest reliability to evalu-
ate the stability of the measure over time. The primary
strength of this study is that it has demonstrated that it is
possible to prospectively measure potential participants’
decision-making about trial participation, albeit in a small
and selective sample underrepresenting those who are
more likely to refuse trial participation. Measuring aspects
related to informed consent (including decision-making)
in a fully representative population of potential trial
participants is very difficult. Most studies in which
investigators have assessed aspects of the trial partici-
pation decision, described earlier, have been conducted
in cancer trials with decisions measured retrospectively,
which may be biased by outcomes attributed to the deci-
sion or at best immediately following the decision (that is,
consent) [10]. A further strength of this study is that we
investigated decision-making across a range of conditions,
clinical areas, geographic sites and recruiters. Additionally,
the nonstandard conceptualisation and operationalisation
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Table 6 Comparison of DelibeRATE tool with existing measures of informed consenta
Instrument Year Population Theoretical/conceptual framework Constructs assessed Items Timing Sample questions
DelibeRATE 2012 Set within three different
parent RCTs: two surgical
and one drug, all phase III
pragmatic RCTs of direct
head-to-head comparisons
Structured around a conceptual
framework informed by theories
of decision-making which separates
decision-making process into
deliberation and determination
1. Information search 10 items Measured before
consent to participate
in trial
I understand the option,
of participating in the trial
or not, is available to me2. Knowledge gain
3. Appraisal of knowledge
sufficiency
4. Imagining counterfactuals I know how I feel about
participating in the trial
or not5. Affective forecasting
6. Preference construction
Quality of Informed
Consent (QuIC) [6]
2001 Patients and parents of
paediatric patients enrolled
in phase I, II or III clinical
trial; tool developed with
intention to be used across
clinical areas
Conceptual framework considered:
existing theoretical work on
therapeutic misconception,
regulations governing research,
recommendations of National
Cancer Institute working group
1. Objective understanding
(part A)
Total = 34 items After consent I have been informed
how long my participation
in this clinical trial is likely
to last (part A)
Part A: Objective
understanding
(n = 20)
2. Subjective understanding
(part B)
Based on 13 domains identified
in regulatory documents on
informed consent
Part B: Subjective
understanding
(n = 14)
The fact that your
treatment involves
research (part B)
Informed Consent
Assessment Instrument
(ICAI) [9]
2013 Set within an open-drug
RCT for tuberculosis
No explicit theory reported Content informed by the
four principles of research
ethics: autonomy, beneficence
nonmaleficence and justice
Total = 10 items Measured right after
time of consent, then
remeasured 8 to 10
weeks after consent
Are you participating
in a clinical trial?
Authors state informed by
principles of research ethics Are the risks and benefits
of taking part in the study
clear?Format informed by QuIC
Brief Informed Consent
Evaluation protocol
(BICEP) [10]
2005 Set within eight different
parent RCTs
No explicit theory reported;
conceptual dimensions:
therapeutic misunderstanding,
voluntariness and understanding
Autonomous authorisation Total = 15 items Measured immediately
after consent process
What is the primary
purpose of [parent
study]?Informed consent
aggregate score
(ICAS) (n = 10) What are the benefits
to you of participating
in the [parent study]?Therapeutic
misconception
aggregate score
(TMAS) (n = 5)
aRCT, Randomised controlled trial.
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of the informed consent process for clinical trials
applied in this study is a further strength. Specifically,
in this study, we approached informed consent as a
decision-making process and measured constructs
associated with a stage of that process rather than
focusing on outcomes such as understanding. A com-
parison of the DelibeRATE tool and commonly used
alterative measures of informed consent is presented in
Table 6. This table highlights the difference in conceptual-
isation and timing of the DelibeRATE tool compared to
existing trial consent measures.
Key recommendations
Decisions about whether to participate in a clinical trial
are suboptimal [4,5]. This is not surprising when one
considers that items important for ‘good’ decision-
making are lacking in existing patient information leaf-
lets for clinical trials [21]. Designers of interventions to
improve the decision-making process have tended to
address understanding by focusing on the content and
structure of provided information [4,5]. The results of
some studies have highlighted the need for new ways of
thinking about assessing the decision-making process
for trial participation. Miller et al. concluded that a
measure of preparation for trial participation decision-
making is needed [8]. In line with this, interventions
that recognise the decision and what it means for parti-
cipants are being developed [22-25]. As these interven-
tions are developed, appropriate measures to evaluate
their effectiveness, which go beyond understanding, are
also required.
More work needs to be done with regard to how to
access the trial refusers so as to measure and explore
their decision-making in more depth to ensure both
consenters and refusers are making decisions in line
with their personal values and preferences. It may be
that studies aimed at measuring decision-making in this
context need to be more embedded in the parent trial,
such that they become invisible and seamless within the
trial. Appropriate ways to engage potential participants
with methods to capture decision-making data should
be explored. For example, using novel methods to
capture data (such as with tablet computers) could have
potential. Moreover, involving patients and the public in
designing studies of this type could improve the
development of the tool and its implementation for data
capture. Further work is also required to develop a tool
that accurately captures the conceptual aspects of deci-
sions about trial participation, being mindful of both the
regulatory framework of informed consent and the goals
and values of the individual. These tools should adopt a
‘fast and frugal’ approach to their measurement, in terms
of both the underlying theoretical framework and their
design and delivery [26].
Conclusions
Our study shows that decisions about trial participation
can be measured prospectively during the recruitment
process in clinical trials in different contexts. However,
further work is required to determine whether the lack
of variability in the DelibeRATE scores in our study
(both at the level of the entire sample and between con-
senters and refusers) is due to the nonvalidated nature
of the tool or to the underrepresentation of trial refusers
in the study sample. We highlight points important to
consider by researchers designing trials and those involved
in the informed consent process, such as recognition that
potential participants may have made a decision about
‘clinical trials’ even before they were invited to participate
and that recruiters may make implicit judgements about
potential participants during the trial recruitment process.
We propose considerations for future studies designed to
measure decision-making in this context and studies em-
bedded within the recruitment process for clinical trials.
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